Stifel affirms Biogen (Nasdaq: BIIB) at Hold after the company and Ionis Pharmaceuticals announced that nusinersen, their investigational treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Biogen (BIIB) PT Raised to $367 at Leerink PartnersAugust 1, 2016 3:18 PM Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284August 1, 2016 3:16 PM Biogen (BIIB) PT Raised to $304 at BMO CapitalAugust 1, 2016 12:44 PM Pharma and tech converge in 'fantastic voyage' to fight diseaseAugust 1, 2016 9:46 AM Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMAAugust 1, 2016 7:34 AM Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular AtrophyAugust 1, 2016 7:30 AM